Influenza vaccines traditionally required yearly redevelopment to address changes in flu strains. With breakthrough technologies, however, the variables of yearly redevelopment can be reduced—accelerating time to market while reducing costs.
Aug 2, 2007
Vaccines against strains originating from avian flu may achieve poor yields in egg-based systems. Consequently, both public and private interest in alternative systems is high.